Mary Caffrey

A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.

In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including large subgroups, such as older women.

Apar Kishor Ganti, MD, chair of the National Comprehensive Cancer Network Guidelines panel in small cell lung cancer, explains the thinking behind several new recommendations.

Due to unprecedented disruption and missed screenings during the pandemic, efforts to implement a 5-year performance period under the Radiation Oncology Model were extended twice.

When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate.

The dialysis company faces a $100M fine for each of 2 antitrust counts.

The new standards come as community oncology practices await word on the future of the oncology care model, which will expire in 2022.

A statement from the makers of the SGLT2 inhibitor empagliflozin suggests the benefits in heart failure with preserved ejection fraction (HFpEF) are significant.

Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.

Abstracts cover the cost of cancer-related diarrhea, 30-day readmission rates, and how perceptions of the likelihood of survival affect end-of-life care.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.

The study was launched the same month as the first US approval of a sodium-glucose co-transporter 2 inhibitor, and the failure to include a drug from this class was viewed by a commentator as a weakness of GRADE.

Sanofi gave up rights to develop the glucagon-like peptide 1 receptor agonist last year after a change in strategy.

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”

The once-weekly therapy is also being studied in nonalcoholic steatohepatitis and heart failure with preserved ejection fraction and obesity.